Letter: Beyond Feasibility: The Need for Longer Duration and Composite NIT Endpoints in Biopsy‐Free MASH Trials
Authors:
- 26 April 2026
- journal article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 64 (2) , 299-300
Abstract
No abstract availableThis publication has 3 references indexed in Scilit:
- Clinical Trial: Semaglutide Versus Placebo in NIT ‐Assessed MASH —A Multicenter Randomised Placebo‐Controlled Trial ( SAMARA )Alimentary Pharmacology & Therapeutics, 2026
- Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated SteatohepatitisNew England Journal of Medicine, 2025
- Head-to-head comparison of MASH resolution index versus FAST for noninvasive prediction of resolution of MASH on biopsyHepatology, 2025